查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012794

抗病毒药物市场：2026-2032年全球市场预测（依适应症、药物类别、给药途径、最终用户和分销管道划分）

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗病毒药物市场价值将达到 628.1 亿美元，到 2026 年将成长至 659.2 亿美元，到 2032 年将达到 1008.3 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年 2025 628.1亿美元
预计年份：2026年 659.2亿美元
预测年份 2032 1008.3亿美元
复合年增长率 (%) 6.99%

为策略领导者提供当前抗病毒治疗趋势的简明概述，整合了科学进步、临床挑战和系统性影响。

抗病毒药物领域正处于一个转折点，治疗方法创新、医疗服务模式转变以及不断变化的监管预期相互交织，重塑研发和商业性模式。本执行摘要整合了适应症、药物类别和分销管道中最关键的趋势，并将其转化为临床团队、商业领导者和供应链负责人所需的策略洞察。其目标是将复杂的跨学科数据以可操作的方式呈现给那些必须在短期营运重点和长期研发规划之间取得平衡的领导者。

对科学、监管和交付方法的创新融合进行详细分析，这些创新正在从根本上重塑抗病毒药物的开发和商业化途径。

抗病毒疗法的研发和应用正经历着许多变革，这些变革正在改变竞争格局和临床环境。生物製药和核酸技术正从概念验证（PoC）阶段迈向成熟的治疗策略，推动着旨在延长药效持续时间、提高遵守用药以及开展靶向性、基于机制干预的治疗项目。同时，诊断和治疗技术的融合使得早期检测和「检测即治疗」模式成为可能，并影响临床试验设计和打入市场策略。

对 2025 年美国关税变化将给采购带来的直接压力以及这些变化将为供应链韧性和製造本地化创造的策略奖励进行全面评估。

美国2025年实施的关税调整的累积影响，正对参与抗病毒治疗的机构在采购、生产和临床运营等各个领域造成多方面的压力。关键化学中间体和某些成品药的进口关税增加了依赖全球供应链的企业的接收成本，迫使采购团队重新思考筹资策略，并考虑将生产外包或选择替代供应商以维持供应的连续性。这种供应商多元化的转变通常需要大量的前置作业时间和资金投入，以选择替代的生产合作伙伴并确保符合监管品质标准。

详细的细分洞察涵盖适应症、治疗领域、给药途径、分销管道和终端用户趋势，从而推动差异化策略。

基于适应症的细分揭示了乙型肝炎、丙型肝炎、单纯疱疹病毒、爱滋病毒、流感和呼吸道融合细胞病毒（RSV）在临床需求和商业策略方面的不同路径。乙型肝炎计画日益重视持续性病毒抑制和功能性治癒策略，这需要长期安全性和生物标记的开发。同时，丙型肝炎计画则着重于简化治疗方法和支持广泛病例发现的获取模式。单纯疱疹的管理仍然着重于控制和预防高风险族群的感染。爱滋病毒研究在探索长效製剂和以治癒为导向的治疗方法的同时，也沿用了现有的慢性病管理模式。流感和呼吸道融合细胞病毒（RSV）计画优先考虑季节性治疗方法和快速诊断，以优化治疗和预防的时机。

一项策略性区域分析，重点阐述了美洲、欧洲、中东和非洲以及亚太地区的监管、临床和製造因素如何影响实际选择。

区域趋势对整个抗病毒药物领域的研发重点、製造地选择和商业化策略的发展至关重要。在美洲，完善的研究基础设施和广泛的临床试验网络为快速转化研究提供了支持，而政策辩论和支付方框架则影响定价策略和准入模式。此外，美洲作为长效製剂和先进治疗方法的主要市场发挥关键作用，并拥有能够处理复杂的基于价值的合约和上市后证据收集的医疗保健系统。

从公司层级切实观点创新、製造策略和伙伴关係模式，这些正在抗病毒药物的开发和商业化中创造竞争优势。

抗病毒疗法领域的企业策略正趋向于几个高影响力优先事项：推动差异化治疗方法的研发、确保强大的生产能力以及在整个生态系统中建立合作伙伴关係。主要企业正在平衡有针对性的授权和共同开发契约，以加速新型机制的获取，同时推动内部创新，并管控技术风险。对能够实现模组化适应多种病毒标靶的平台技术的投资，正在加速从药物发现到临床候选药物的转化。企业也越来越重视那些具有明确路径、能够提高遵守用药并减少密集监控需求的资产。

针对抗病毒药物领域，提出具体且高度优先的建议，以促进研发、生产韧性、与支付者合作以及商业性实施，从而推动抗病毒药物领域的持续成功。

产业领导企业应优先采取一系列切实可行的措施，使研发选择与商业性执行和供应链韧性保持一致。首先，应加快对长效和标靶给药方式的投资，以显着提高用药依从性并减轻医疗系统的负担，同时制定完善的真实世界数据收集计划，以支持医保报销，并配合临床开发计划。其次，应透过选择区域合作伙伴和灵活的契约製造来实现製造地的多元化，并纳入情境规划，以应对关税波动和原材料短缺，从而最大限度地降低临床试验和商业供应的风险。

对多方面的调查方法进行透明的解释，这些方法结合了专家访谈、监管和科学审查以及情境分析，以检验实际见解。

本执行摘要的研究采用多方面方法，交叉引用专家访谈、二手文献、监管申报文件和技术资料来源，以确保提供全面且检验的见解。一手资讯来源包括对临床研究人员、供应链经理、监管专家和商业领域领导者的结构化访谈，从而提供关于营运挑战、临床重点和支付方期望的实地观点。二手研究涵盖同侪审查文献、临床试验註册资料、专利趋势和已发布的监管决策，以捕捉科学趋势和开发平臺。

最终整合关键策略重点，将科学预期转化为抗病毒治疗领域坚实的临床和商业性成功。

总之，抗病毒疗法正进入一个技术快速发展、供应链日益复杂、市场准入要求不断变化的时期。科学进步为透过长效药物和标靶治疗方法改善患者预后提供了明确的途径，但其成功实用化需要灵活的生产策略、整合的诊断方法以及与支付方的有效沟通。区域监管预期与关税驱动的供应动态之间的交互作用凸显了在地化实施和完善的紧急时应对计画的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗病毒药物市场：依适应症划分

  • B型肝炎
  • C型肝炎
  • 单纯疱疹
  • HIV
  • 流感
  • 呼吸道融合细胞病毒

第九章：抗病毒药物市场：依药物类别划分

  • 融合抑制剂
  • 整合酶抑制剂
  • 非核苷类逆转录酶抑制剂
  • 核苷类似物
  • 蛋白酶抑制剂

第十章：抗病毒药物市场：依给药途径划分

  • 吸入
  • 注射药物
  • 口服
  • 外用

第十一章：抗病毒药物市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院
  • 长期照护机构

第十二章 抗病毒药物市场：依分销管道划分

  • 诊所
  • 医院药房
  • 网路药房
  • 零售药房

第十三章 抗病毒药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗病毒药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 抗病毒药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗病毒药物市场

第十七章：中国抗病毒药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market was valued at USD 62.81 billion in 2025 and is projected to grow to USD 65.92 billion in 2026, with a CAGR of 6.99%, reaching USD 100.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.81 billion
Estimated Year [2026] USD 65.92 billion
Forecast Year [2032] USD 100.83 billion
CAGR (%) 6.99%

Concise orientation to the current antiviral therapeutics landscape that synthesizes scientific advances, clinical pressures, and system implications for strategic leaders

The antiviral drugs landscape is at an inflection point where therapeutic innovation, shifting care delivery models, and evolving regulatory expectations intersect to reshape research, development, and commercial approaches. This executive summary synthesizes the most consequential developments across indications, drug classes, and distribution channels, and it translates those developments into strategic implications for clinical teams, commercial leaders, and supply chain executives. The goal is to present an actionable condensation of complex, cross-disciplinary data for leaders who must balance near-term operational priorities with longer-term R&D pathways.

To ensure relevance across stakeholder groups, the analysis foregrounds clinical unmet needs, technology enablers, and system pressures that are redefining how antiviral therapies are developed and delivered. The narrative integrates scientific trajectories-such as advances in antiviral modalities and diagnostics-with practical considerations including procurement practices, payer engagement, and the operationalization of outpatient care. Throughout, emphasis is placed on decisions that influence patient access, therapeutic value, and resilience against supply disruptions, providing a concise yet nuanced orientation for planning and investment decisions.

Detailed analysis of the converging scientific, regulatory, and delivery innovations that are fundamentally reshaping development and commercialization pathways for antivirals

A number of transformative shifts are altering the competitive and clinical contours of antiviral therapy development and delivery. Biologic modalities and nucleic acid technologies have moved from proof-of-concept stages into validated therapeutic strategies, fueling programs that aim to deliver longer duration of effect, improved adherence, and targeted mechanism-based interventions. Concurrently, diagnostics are converging with therapeutics to enable earlier detection and test-and-treat paradigms, which in turn influence clinical trial design and commercial access strategies.

Regulatory pathways have adjusted to accommodate accelerated development in high-need areas, and payers are increasingly tying reimbursement to demonstrable real-world outcomes and health economic value. Digital health tools are being integrated into patient monitoring and adherence programs, supporting decentralized care models and shifting utilization away from inpatient settings when clinically appropriate. Manufacturing innovation, including flexible biologics capacity and modular production techniques, is reducing lead times and enabling regionalized supply chains. These shifts collectively create a landscape in which agility, cross-sector partnerships, and rapid evidence generation determine who can translate scientific promise into durable clinical and commercial success.

Comprehensive assessment of how the 2025 United States tariff changes create immediate procurement pressures and strategic incentives for supply chain resilience and manufacturing localization

The cumulative effect of the United States tariff adjustments enacted in 2025 introduces multifaceted pressures across procurement, manufacturing, and clinical operations for organizations engaged in antiviral therapeutics. Import duties on key chemical intermediates and selected finished pharmaceuticals have increased landed costs for firms that rely on global supply networks, prompting procurement teams to reassess sourcing strategies and to explore nearshoring or alternate supplier qualification to maintain continuity. This reorientation toward supplier diversification often requires significant lead time and capital investment to qualify alternate manufacturing partners and to ensure compliance with regulatory quality standards.

Clinics and hospital systems face increased variability in procurement pricing, which in turn affects purchasing cycles and inventory policies; some institutions are extending inventory buffers while others are negotiating longer term purchasing agreements to mitigate volatility. For developers, tariff-driven cost pressures can change the calculus for where and how manufacturing scale-up is executed, potentially favoring regional production hubs that reduce exposure to cross-border duties despite higher local operating costs. The tariffs also influence the dynamics of contract manufacturing organizations, as increased demand for domestic or qualified regional capacity creates competitive pressure on timelines and pricing.

Policy responses and private sector strategies are emerging to offset impacts, including targeted supply agreements, increased vertical integration, and strategic stockpiling for critical active pharmaceutical ingredients. These adjustments have downstream effects on the speed of clinical trial material provisioning, the cost base for pricing negotiations with payers and procurers, and the prioritization of therapeutic pipelines that require fewer complex inputs. In aggregate, the tariff environment accelerates a strategic shift toward resilience and redundancy in supply chains while elevating the importance of cost containment through process innovation and manufacturing efficiency.

In-depth segmentation insights spanning indications, therapeutic classes, administration routes, distribution channels, and end-user dynamics driving differentiated strategies

Segmentation by indication reveals differentiated pathways of clinical need and commercial strategy across Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, and Respiratory Syncytial Virus. Hepatitis B programs are increasingly focused on durable viral suppression and functional cure strategies, demanding long-term safety and biomarker development, whereas Hepatitis C efforts emphasize simplified regimens and access models that support broad case finding. Herpes Simplex management remains concentrated on episodic control and prophylaxis for high-risk populations, while HIV research balances long-acting formulations and cure-directed approaches alongside established chronic care models. Influenza and Respiratory Syncytial Virus programs prioritize seasonally responsive therapies and rapid diagnostics to optimize timing of treatment and prophylaxis.

When viewed by drug class, priorities vary between Fusion Inhibitors, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogues, and Protease Inhibitors. Integrase and fusion inhibitors are attracting interest for novel resistance profiles and tolerability advantages, while nucleoside analogues and protease inhibitors remain foundational for established regimens that require careful lifecycle management. Non-Nucleoside Reverse Transcriptase Inhibitors continue to be evaluated for improved safety profiles and combination strategies that enhance durability and adherence.

Routes of administration, spanning inhalation, injectable, oral, and topical, shape patient adherence, distribution logistics, and clinical setting. Oral therapies remain central for outpatient management and chronic disease maintenance, injectables and long-acting formulations support adherence and reduce clinic visit frequency, inhalation therapeutics offer targeted pulmonary exposure for respiratory viruses, and topical formulations maintain relevance for mucocutaneous infections where localized delivery improves tolerability.

Distribution channel dynamics across clinics, hospital pharmacies, online pharmacies, and retail pharmacies influence access, reimbursement pathways, and point-of-care decisioning. Clinics and hospital pharmacies often handle complex regimens and parenteral products supported by institutional procurement processes, while online and retail pharmacies expand reach and convenience for oral and topical therapies. Finally, end user segmentation that includes clinics, home care, hospitals, and long term care facilities highlights the importance of care setting in therapeutic choice, with home care and outpatient clinics driving demand for user-friendly formulations and simplified monitoring protocols, and hospitals and long term care facilities requiring robust supply and administration workflows for complex regimens.

Strategic regional considerations highlighting how distinct regulatory, clinical, and manufacturing factors in the Americas, Europe Middle East & Africa, and Asia-Pacific shape execution choices

Regional dynamics are central to shaping R&D priorities, manufacturing placement, and commercialization approaches across the antiviral landscape. In the Americas, established research infrastructure and widespread clinical trial networks support rapid translational efforts, while policy debates and payer frameworks influence pricing strategies and access models. The Americas also function as a key market for long-acting and advanced modality launches, with healthcare systems that can absorb complex value-based contracting and post-launch evidence collection.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with varied reimbursement landscapes. European regulatory frameworks favor robust comparative effectiveness and health economic evidence, motivating manufacturers to invest in real-world data generation and payer engagement early in development. The Middle East & Africa region presents distinct access challenges and opportunities for public-private partnerships focused on manufacturing capacity building and distribution networks that reach underserved populations.

Asia-Pacific is a diverse region that combines rapidly expanding R&D investment, large patient populations with significant unmet needs, and emerging manufacturing prowess. Several economies within Asia-Pacific are investing heavily in both small molecule and biologics manufacturing, and favorable policy incentives are accelerating clinical development throughput. Commercial strategies in the region must reconcile heterogenous payer systems, variable patient affordability, and the increasing role of digital channels for patient engagement and distribution. Across all regions, successful programs are those that tailor evidence generation, supply chain design, and commercial models to local regulatory expectations and care delivery realities.

Practical company-level perspectives on innovation, manufacturing strategy, and partnership models that are driving competitive advantage in antiviral development and commercialization

Company strategies in antiviral therapeutics are converging on a few high-impact priorities: advancing differentiated modalities, securing resilient manufacturing capacity, and forging collaborative partnerships across the ecosystem. Leading developers are balancing in-house innovation with targeted licensing and co-development agreements that accelerate access to novel mechanisms while managing technical risk. Investment in platform technologies that enable modular adaptation across viral targets is enabling faster transition from discovery to clinical candidate, and companies are increasingly prioritizing assets with clear pathways to improved adherence or reduced need for intensive monitoring.

Operationally, firms are bolstering supply chain integration and expanding capacity through selective vertical moves or strategic manufacturing partnerships to reduce exposure to cross-border cost shocks. Commercially, organizations are experimenting with value-based contracting and payer partnerships that align long-term outcomes with reimbursement structures, while specialist commercialization teams focus on differentiated channels such as hospital formularies and specialty pharmacies. Smaller biotech firms are leveraging nimble development processes and focused proof-of-concept studies to attract partnerships, while larger multinational pharmaceutical companies provide scale, regulatory expertise, and access to global distribution networks. Across company types, success increasingly depends on the ability to translate clinical differentiation into demonstrable patient and system value and to operationalize that value across complex care pathways.

Concrete and prioritized recommendations for R&D prioritization, manufacturing resilience, payer engagement, and commercial execution to drive durable success in antivirals

Industry leaders should prioritize a suite of actionable measures that align R&D choices with commercial execution and supply chain resilience. First, accelerate investment in long-acting and targeted delivery modalities that demonstrably improve adherence and reduce system burden, pairing clinical development plans with robust plans for real-world evidence collection to support reimbursement. Second, diversify manufacturing footprints by qualifying regional partners and flexible contract manufacturers, and incorporate scenario planning for tariff-driven disruptions and input scarcity to minimize risks to clinical trials and commercial supply.

Third, design launch strategies that integrate diagnostics and telehealth pathways, enabling rapid identification of treatment-eligible patients and reducing barriers to initiation. Fourth, engage payers early to define evidence requirements and to explore outcome-based reimbursement structures that share risk and reward. Fifth, cultivate strategic alliances that pair platform technologies with commercialization expertise, whether through co-development, licensing, or targeted acquisitions that fill capability gaps. Sixth, invest in digital and patient support programs that improve adherence, collect outcome data, and reduce the total cost of care. Finally, embed sustainability into procurement and manufacturing decisions to reduce exposure to geopolitical and tariff pressures while meeting growing stakeholder expectations for resilient and responsible operations.

Transparent description of the multi-method research approach combining expert interviews, regulatory and scientific review, and scenario analysis to validate actionable insights

The research underpinning this executive summary draws on a multi-method approach that triangulates primary expert interviews, secondary literature, regulatory filings, and technical data sources to ensure comprehensive and validated insights. Primary inputs included structured interviews with clinical investigators, supply chain managers, regulatory experts, and commercial leaders, providing ground-level perspectives on operational challenges, clinical priorities, and payer expectations. Secondary review encompassed peer-reviewed literature, clinical trial registries, patent landscapes, and public regulatory decisions to map scientific trends and development pipelines.

Analytical methods included qualitative thematic synthesis to identify recurrent strategic themes, comparative policy analysis to discern regional regulatory implications, and scenario planning to evaluate supply chain and tariff impacts. Quality assurance was maintained through cross-validation of interview findings with document review and by presenting interim themes to an independent panel of subject matter experts for feedback. The methodology acknowledges limitations inherent to horizon scanning and expert elicitation, including potential sampling bias in interview subjects and the rapidly evolving nature of clinical research; these limitations were mitigated through diverse stakeholder engagement and repeated validation cycles. The resulting insights prioritize robustness and practical relevance for decision makers seeking to align near-term operational imperatives with longer-term strategic objectives.

Final synthesis of the critical strategic priorities for converting scientific promise into durable clinical and commercial success in antiviral therapeutics

In summation, antiviral therapeutics are entering a period defined by technological momentum, heightened supply chain complexity, and evolving market access requirements. Scientific advances provide clear pathways to improved patient outcomes through longer-acting agents and targeted modalities, yet successful translation depends on adaptive manufacturing strategies, integrated diagnostics, and sophisticated payer engagement. The interplay of regional regulatory expectations and tariff-driven supply dynamics underscores the importance of localized execution and robust contingency planning.

Leaders who align clinical development with pragmatic proofs of value, diversify manufacturing and procurement approaches, and invest in digital tools for adherence and evidence capture will be best positioned to convert scientific potential into accessible therapies. The recommendations contained in this summary are intended to guide immediate operational decisions while supporting longer-term investments that build durable competitive advantage. Organizations that act with both tactical responsiveness and strategic foresight can mitigate near-term disruptions and unlock sustainable growth opportunities in the evolving antiviral landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs Market, by Indication

  • 8.1. Hepatitis B
  • 8.2. Hepatitis C
  • 8.3. Herpes Simplex
  • 8.4. Hiv
  • 8.5. Influenza
  • 8.6. Respiratory Syncytial Virus

9. Antiviral Drugs Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Non Nucleoside Reverse Transcriptase Inhibitors
  • 9.4. Nucleoside Analogues
  • 9.5. Protease Inhibitors

10. Antiviral Drugs Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Long Term Care Facilities

12. Antiviral Drugs Market, by Distribution Channel

  • 12.1. Clinics
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Antiviral Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antiviral Drugs Market

17. China Antiviral Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca plc
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim GmbH
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Hetero Labs Limited
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co., Inc.
  • 18.18. Mylan N.V.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Roche Holding AG
  • 18.22. Sandoz International GmbH
  • 18.23. Sanofi S.A.
  • 18.24. Sun Pharmaceutical Industries Ltd.
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)